ACCD Quote, Financials, Valuation and Earnings

HealthStream has a net margin of -22.5% compared to Accolade's net margin of 7.83%. Accolade's return on equity of -18.4% beat HealthStream's return on equity of 5.69%.

Accolade has a consensus price target of $7.17, signalling upside risk potential of 114.15%. On the other hand HealthStream has an analysts' consensus of -- which suggests that it could grow by 0.78%. Given that Accolade has higher upside potential than HealthStream, analysts believe Accolade is more attractive than HealthStream.

Accolade has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison HealthStream has a beta of 0.396, suggesting its less volatile than the S&P 500 by 60.425%.

Accolade has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HealthStream offers a yield of 0.43% to investors and pays a quarterly dividend of $0.03 per share. Accolade pays -- of its earnings as a dividend. HealthStream pays out 20.1% of its earnings as a dividend. HealthStream's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Accolade quarterly revenues are $106.4M, which are larger than HealthStream quarterly revenues of $73.1M. Accolade's net income of -$23.9M is lower than HealthStream's net income of $5.7M. Notably, Accolade's price-to-earnings ratio is -- while HealthStream's PE ratio is 49.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accolade is 0.59x versus 3.42x for HealthStream. Usually stocks with elevated PS ratios are considered overvalued.

Schrodinger has a net margin of -22.5% compared to Accolade's net margin of -108.07%. Accolade's return on equity of -18.4% beat Schrodinger's return on equity of -34.83%.

Accolade has a consensus price target of $7.17, signalling upside risk potential of 114.15%. On the other hand Schrodinger has an analysts' consensus of -- which suggests that it could grow by 51.3%. Given that Accolade has higher upside potential than Schrodinger, analysts believe Accolade is more attractive than Schrodinger.

Accolade has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Schrodinger has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Accolade has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Schrodinger offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accolade pays -- of its earnings as a dividend. Schrodinger pays out -- of its earnings as a dividend.

Accolade quarterly revenues are $106.4M, which are larger than Schrodinger quarterly revenues of $35.3M. Accolade's net income of -$23.9M is higher than Schrodinger's net income of -$38.1M. Notably, Accolade's price-to-earnings ratio is -- while Schrodinger's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accolade is 0.59x versus 8.01x for Schrodinger. Usually stocks with elevated PS ratios are considered overvalued.

Simulations Plus has a net margin of -22.5% compared to Accolade's net margin of 4.52%. Accolade's return on equity of -18.4% beat Simulations Plus's return on equity of 5.64%.

Accolade has a consensus price target of $7.17, signalling upside risk potential of 114.15%. On the other hand Simulations Plus has an analysts' consensus of $50.00 which suggests that it could grow by 64.53%. Given that Accolade has higher upside potential than Simulations Plus, analysts believe Accolade is more attractive than Simulations Plus.

Accolade has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Simulations Plus has a beta of 0.797, suggesting its less volatile than the S&P 500 by 20.306%.

Accolade has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Simulations Plus offers a yield of 0.79% to investors and pays a quarterly dividend of $0.06 per share. Accolade pays -- of its earnings as a dividend. Simulations Plus pays out 48.18% of its earnings as a dividend. Simulations Plus's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Accolade quarterly revenues are $106.4M, which are larger than Simulations Plus quarterly revenues of $18.7M. Accolade's net income of -$23.9M is lower than Simulations Plus's net income of $843K. Notably, Accolade's price-to-earnings ratio is -- while Simulations Plus's PE ratio is 62.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accolade is 0.59x versus 8.82x for Simulations Plus. Usually stocks with elevated PS ratios are considered overvalued.